Abstract: The composition according to the present invention, which comprises Lactococcus chungangensis as an active ingredient, has excellent effects of preventing or treating inflammatory diseases, inhibiting the secretion of nitric oxide and prostaglandin E2, which are major inflammatory factors, and inhibiting the secretion of ?-hexosaminidase and histamine, which are major factors related to allergies, and also significantly suppressing the production of skin disease-related cytokines and chemokines. Such effects are at the same level as those of conventional skin disease therapeutic agents (tacrolimus), and thus the composition can be used as a preventive or therapeutic agent against inflammatory diseases. In addition, the composition according to the present invention exhibits an antibacterial activity against Staphylococcus aureus, which is a microorganism inducing a secondary infection of atopic dermatitis and the like, and thus can be used in preventing or treating a bacterial infection.
Type:
Grant
Filed:
September 27, 2017
Date of Patent:
September 17, 2019
Assignee:
Chung-Ang University Industry-Academic Cooperation Foundation
Abstract: Disclosed herein are pest controlling compositions (i.e., biopesticides) comprising one or more entomopathogenic fungi which. Further disclosed are methods of using such compositions for controlling invasive pests, particularly agriculturally relevant pests.
Type:
Grant
Filed:
November 5, 2014
Date of Patent:
August 20, 2019
Assignee:
NOVOZYMES BIOAG A/S
Inventors:
Kenneth Edmund Kellar, Emily Looze, Jarrod Leland
Abstract: The invention analyzed a protein sequence using the Udwary-Merski algorithm and identified a tetradomain fragment (DH1-DH2-UMA) which consists of two predicted DH-like domains and two pseudodomains N-terminal to them. This arrangement of domains and pseudodomains is fundamentally the opposite of what is typically observed in the DH cassettes of actinobacterial polyketide synthases or mammalian fatty acid synthases, both of which feature C-terminal pseudodomains. The invention modified E. coli by over expressing DH1-DH2-UMA in E. coli resulting in an increase in the overall production of all the fatty acids normally present in the E. coli fatty acid profile.
Abstract: The present disclosure provides immunomodulatory compositions comprising heat-killed Caulobacter crescentus (HKCC). Immunomodulatory compositions of the present disclosure are useful for modulating an immune response in an individual. The present disclosure thus provides methods of modulating an immune response in an individual, involving administering an immunomodulatory composition comprising HKCC to the individual.
Abstract: Compositions of either the Rm86Texas protein from a Texas outbreak strain of the southern cattle fever tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this Rm86Texas protein, are effective for eliciting a protective immune response in non-bovine animals. The Rm86Texas protein is immunogenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks. Moreover, as ticks are vectors of a variety of pathogens, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogens in susceptible animals.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
July 30, 2019
Assignees:
The United States of America, as Represented by the Secretary of Agriculture, Board of Supervisors of Louisiana State University and Agriculture and Mechanical Colloge
Inventors:
Andrew Y. Li, Felicito Guerrero, Lane D. Foil, Adalberto A. Perez De Leon
Abstract: The invention provides compositions and methods for clostridial bacteria that have been engineered to produce and/or to improve efficiency of production of industrial bioproducts.
Abstract: Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.
Type:
Grant
Filed:
December 23, 2014
Date of Patent:
July 23, 2019
Assignee:
Emergent Product Development Gaithersburg Inc.
Inventors:
Jee Look, Christian Fernando Ruiz, Aaron Paul Miles, Richard William Welch
Abstract: This invention relates generally to molecules that specifically bind bacterial V-tip proteins of the type III secretion system of Gram negative bacteria such as PcrV from Pseudomonas aeruginosa. More specifically, this invention relates to molecules that block the injection of effector molecules into target cells. This invention also relates to molecules that specifically bind to bacterial lipoproteins, such as OprI. The molecules of the present invention are monospecific or multispecific and can bind their target antigen in a monovalent or multivalent manner. The invention also relates generally to molecules that specifically bind bacterial cell surface proteins such as OprI, and to methods of use these molecules in a variety of therapeutic, diagnostic, and/or prophylactic indications.
Type:
Grant
Filed:
May 2, 2016
Date of Patent:
July 9, 2019
Assignee:
Inhibrx, Inc.
Inventors:
Andrew Hollands, John C. Timmer, Quinn Deveraux, Brendan P. Eckelman
Abstract: An agent for use in a vaccine therapy to prevent or treat a Burkholderia infection in a mammal, wherein the agent is selected from a polypeptide of SEQUENCE ID NO:1, or a therapeutically effective variant thereof having at least 90% sequence identity with SEQUENCE ID NO: 1; a polypeptide of SEQUENCE ID NO:3, or a therapeutically effective variant thereof having at least 90% sequence identity with SEQUENCE ID NO: 3; and an immunogenic portion of the polypeptides of SEQUENCE ID NO:1 or SEQUENCE ID NO:3.
Abstract: Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual.
Abstract: The present invention relates to a composition for the prevention or treatment of arthritis, the composition containing a Sargassum serratifolium extract as an active ingredient. The extract of Sargassum serratifolium according to the present invention has an excellent activity to reduce or inhibit the activity of IL-1?, IL-6, or TNF-?, which is an inflammatory cytokine, and has an excellent effect alleviating arthritis in an arthritis animal model so that it can be usefully used as a composition for treating arthritis. In addition, there is no cytotoxicity, and toxicity to the drug and side effects are avoided so that it can be safely used even for long-term use, and it is stable in the body.
Type:
Grant
Filed:
February 11, 2016
Date of Patent:
May 14, 2019
Assignee:
Pukyong National University Industry-University Cooperation Foundation
Inventors:
Hyeung-Rak Kim, Mi-Sung Kwon, Eun-Ji Joung
Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
April 16, 2019
Assignee:
National Research Council of Canada
Inventors:
Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
Abstract: A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device. The defined surrogate protein having the predetermined sequence is subjected to sterilization, deimmunization, or disinfection. The effectiveness of the sterilization deimmunization, or disinfection is rapidly determined by determining if the defined surrogate protein has been destroyed.
Abstract: The present invention relates to methods for the production of heat shock protein complexes for use in vaccine compositions. In particular, there is provided a method for increasing the level and immunogenicity of heat shock protein complexes produced in cells by subjecting the cells to specific stress inducing stimuli. The invention further extends to the use of heat shock protein complexes produced according to the methods of the invention in the preparation of vaccine compositions for the prevention and treatment of infectious diseases and cancerous conditions.
Abstract: Disclosed herein are materials and methods for achieving sequence-specific organism detection and/or phenotype(s) using sequence-specific oligonucleotides. Also disclosed are related kits, cultures, and cells for detecting and/or phenotyping microorganisms in a sequence-specific manner.
Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
Type:
Grant
Filed:
December 15, 2015
Date of Patent:
March 5, 2019
Assignee:
THE TEXAS A&M UNIVERSITY SYSTEM
Inventors:
Thomas A. Ficht, Allison Ficht, Renee Tsolis, Leslie Garry Adams
Abstract: The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
February 26, 2019
Assignee:
Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.
Inventors:
Holger Spiegel, Alexander Boes, Gueven Edgue, Veronique Beiss, Markus Sack, Andreas Reimann, Rainer Fischer
Abstract: The present disclosure describes methods for concentrating microorganisms with concentration agents in a sampling device and the sampling device described herein. More specifically, methods for concentrating microorganisms from large volume samples with concentration agents in a sampling device can provide for rapid, low cost, simple (involving no complex equipment or procedures), and/or effective processes under a variety of conditions.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
February 19, 2019
Assignee:
3M Innovative Properties Company
Inventors:
Manjiri T. Kshirsagar, Kurt J. Halverson, Neil Percy, James E. Aysta
Abstract: A supplement composition formulated to support the health of a human's hair skin and nails containing biotin, Haematococcus pluvialis algae, and Reishi.